Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Jun;81(12):3910–3914. doi: 10.1073/pnas.81.12.3910

Dopamine receptor turnover rates in rat striatum are age-dependent.

S E Leff, R Gariano, I Creese
PMCID: PMC345332  PMID: 6587399

Abstract

The time course of recovery of [3H]spiperone binding in the rat striatum after a single injection of the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) shows that a slower rate of regeneration/turnover of D-2 dopamine receptors occurs in mid-life-mature versus young male rats. This slower receptor recovery reflects relatively slower rates of both receptor synthesis and degradation. Studies using cycloheximide indicate that protein synthesis plays a significant role in the reappearance of [3H]spiperone-binding sites. Other experiments indicate that chronic reserpine treatment, which produces dopamine receptor up regulation, also produces accelerated receptor recovery after EEDQ blockade. An age-related decline in dopamine receptor turnover, if present in humans and progressive into senescence, could be responsible for the increased risk of developing Parkinson disease and drug-induced parkinsonian-like extrapyramidal side effects with age. On the other hand, the more rapid receptor turnover rates seen in young rats may be a biochemical feature related to plasticity in the striatum during development.

Full text

PDF
3910

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belleau B., Martel R., Lacasse G., Ménard M., Weinberg N. L., Perron Y. G. N-carboxylic acid esters of 1,2- and 1,4-dihydroquinolines. A new class of irreversible inactivators of the catecholamine alpha receptors and potent central nervous system depressants. J Am Chem Soc. 1968 Jan 31;90(3):823–824. doi: 10.1021/ja01005a067. [DOI] [PubMed] [Google Scholar]
  2. Burt D. R., Creese I., Snyder S. H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977 Apr 15;196(4287):326–328. doi: 10.1126/science.847477. [DOI] [PubMed] [Google Scholar]
  3. Creese I., Sibley D. R., Hamblin M. W., Leff S. E. The classification of dopamine receptors: relationship to radioligand binding. Annu Rev Neurosci. 1983;6:43–71. doi: 10.1146/annurev.ne.06.030183.000355. [DOI] [PubMed] [Google Scholar]
  4. Fambrough D. M. Control of acetylcholine receptors in skeletal muscle. Physiol Rev. 1979 Jan;59(1):165–227. doi: 10.1152/physrev.1979.59.1.165. [DOI] [PubMed] [Google Scholar]
  5. Greenberg L. H., Weiss B. Ability of aged rats to alter beta adrenergic receptors of brain in response to repeated administration of reserpine and desmethylimipramine. J Pharmacol Exp Ther. 1979 Nov;211(2):309–316. [PubMed] [Google Scholar]
  6. Greenberg L. H., Weiss B. beta-Adrenergic receptors in aged rat brain: reduced number and capacity of pineal gland to develop supersensitivity. Science. 1978 Jul 7;201(4350):61–63. doi: 10.1126/science.208145. [DOI] [PubMed] [Google Scholar]
  7. Hall M. D., Jenner P., Marsden C. D. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. Biochem Pharmacol. 1983 Oct 1;32(19):2973–2977. doi: 10.1016/0006-2952(83)90405-7. [DOI] [PubMed] [Google Scholar]
  8. Hamblin M. W., Creese I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci. 1983 May 9;32(19):2247–2255. doi: 10.1016/0024-3205(83)90423-x. [DOI] [PubMed] [Google Scholar]
  9. Hamblin M. W., Leff S. E., Creese I. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochem Pharmacol. 1984 Mar 15;33(6):877–887. doi: 10.1016/0006-2952(84)90441-6. [DOI] [PubMed] [Google Scholar]
  10. Hirschhorn I. D., Makman M. H., Sharpless N. S. Dopamine receptor sensitivity following nigrostriatal lesion in the aged rat. Brain Res. 1982 Feb 25;234(2):357–368. doi: 10.1016/0006-8993(82)90875-7. [DOI] [PubMed] [Google Scholar]
  11. Joseph J. A., Berger R. E., Engel B. T., Roth G. S. Age-related changes in the nigrostriatum: a behavioral and biochemical analysis. J Gerontol. 1978 Sep;33(5):643–649. doi: 10.1093/geronj/33.5.643. [DOI] [PubMed] [Google Scholar]
  12. Joseph J. A., Filburn C. R., Roth G. S. Development of dopamine receptor denervation supersensitivity in the neostriatum of the senescent rat. Life Sci. 1981 Aug 10;29(6):575–584. doi: 10.1016/0024-3205(81)90435-5. [DOI] [PubMed] [Google Scholar]
  13. Kasuga M., Kahn C. R., Hedo J. A., Van Obberghen E., Yamada K. M. Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor degradation. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6917–6921. doi: 10.1073/pnas.78.11.6917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marshall J. F., Drew M. C., Neve K. A. Recovery of function after mesotelencephalic dopaminergic injury in senescence. Brain Res. 1983 Jan 24;259(2):249–260. doi: 10.1016/0006-8993(83)91255-6. [DOI] [PubMed] [Google Scholar]
  15. Martel R. R., Berman R., Belleau B. Pharmacology of EEDQ (N-ethoxycarbonyl-2-ethoxy-1-2-dilhydroquinoline). Can J Physiol Pharmacol. 1969 Oct;47(10):909–912. doi: 10.1139/y69-148. [DOI] [PubMed] [Google Scholar]
  16. Mauger J. P., Sladeczek F., Bockaert J. Characteristics and metabolism of alpha 1 adrenergic receptors in a nonfusing muscle cell line. J Biol Chem. 1982 Jan 25;257(2):875–879. [PubMed] [Google Scholar]
  17. McKernan R. M., Campbell I. C. Measurement of alpha-adrenoceptor "turnover' using phenoxybenzamine. Eur J Pharmacol. 1982 May 21;80(2-3):279–280. doi: 10.1016/0014-2999(82)90070-x. [DOI] [PubMed] [Google Scholar]
  18. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  19. Muren J. F., Weissman A. Depressant 1,2-dihydroquinolines and related derivatives. J Med Chem. 1971 Jan;14(1):49–53. doi: 10.1021/jm00283a013. [DOI] [PubMed] [Google Scholar]
  20. Noble E. P., Wurtman R. J., Axelrod J. A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the rat brain. Life Sci. 1967 Feb 1;6(3):281–291. doi: 10.1016/0024-3205(67)90157-9. [DOI] [PubMed] [Google Scholar]
  21. Pardo J. V., Creese I., Burt D. R., Snyder S. H. Ontogenesis of dopamine receptor binding in the corpus striatum of the rat. Brain Res. 1977 Apr 15;125(2):376–382. doi: 10.1016/0006-8993(77)90633-3. [DOI] [PubMed] [Google Scholar]
  22. Pitha J., Hughes B. A., Kusiak J. W., Dax E. M., Baker S. P. Regeneration of beta-adrenergic receptors in senescent rats: a study using an irreversible binding antagonist. Proc Natl Acad Sci U S A. 1982 Jul;79(14):4424–4427. doi: 10.1073/pnas.79.14.4424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Randall P. K., Severson J. A., Finch C. E. Aging and the regulation of striatal dopaminergic mechanisms in mice. J Pharmacol Exp Ther. 1981 Dec;219(3):695–700. [PubMed] [Google Scholar]
  24. Reed B. C., Lane M. D. Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes. Proc Natl Acad Sci U S A. 1980 Jan;77(1):285–289. doi: 10.1073/pnas.77.1.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roth G. S., Hess G. D. Changes in the mechanisms of hormone and neurotransmitter action during aging: current status of the role of receptor and post-receptor alterations. A review. Mech Ageing Dev. 1982 Nov;20(3):175–194. doi: 10.1016/0047-6374(82)90086-0. [DOI] [PubMed] [Google Scholar]
  26. Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed] [Google Scholar]
  27. Sibley D. R., De Lean A., Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem. 1982 Jun 10;257(11):6351–6361. [PubMed] [Google Scholar]
  28. Sibley D. R., Leff S. E., Creese I. Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sci. 1982 Aug 16;31(7):637–645. doi: 10.1016/0024-3205(82)90764-0. [DOI] [PubMed] [Google Scholar]
  29. Sladeczek F., Bockaert J. Turnover in vivo of alpha 1-adrenergic receptors in rat submaxillary glands. Mol Pharmacol. 1983 Mar;23(2):282–288. [PubMed] [Google Scholar]
  30. Weiss B., Greenberg L., Cantor E. Age-related alterations in the development of adrenergic denervation supersensitivity. Fed Proc. 1979 Apr;38(5):1915–1921. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES